The Federal Institute for Drugs and Medical Devices (BfArM) is set to enhance access to vital pharmaceutical information by expanding its database, which includes drug information such as usage instructions and ingredient compositions. The BfArM is responsible for regulating pharmaceuticals and maintains several databases as part of its pharmaceutical information system, known as AMIce. These databases have been tailored to meet the needs of various user groups. Starting from mid-February 2025, the BfArM will make data that was previously available only through a paid service accessible to the public free of charge. This initiative will include comprehensive information on pharmaceuticals, such as pharmacovigilance data, product marketability, and regulatory status, all aimed at improving public access to reliable information. The BfArM emphasizes the importance of providing verified data amidst a landscape of varying quality information available online. This move aims to facilitate easier access to officially reviewed data from regulatory authorities. The BfArM noted that it is only logical for pharmaceutical information meant for public dissemination to be freely accessible. The database will provide details on all pharmaceuticals authorized for sale in Germany since the introduction of the Drug Act in 1978, as well as information on products that have since lost their approval or registration. Users will be able to access historical data on medications and find additional resources such as professional and user information, public assessment reports, and risk management plans. This expansion is part of broader efforts to ensure that healthcare providers, patients, and the general public have access to accurate and comprehensive information about medications. The BfArM's initiative aligns with ongoing commitments to transparency and public health education, reflecting the agency's dedication to fostering informed decision-making regarding pharmaceutical therapies. In related news, the Gematik organization is preparing to launch a nationwide electronic patient record (EPA) system by next year, providing pharmacies with free informational packages to assist in addressing patient inquiries. Concurrently, the European Medicines Agency (EMA) is investigating potential suicide risks associated with certain medications, including Finasteride and Dutasteride, underscoring the ongoing scrutiny and regulation within the pharmaceutical sector. Furthermore, the BfArM is working collaboratively with the Paul Ehrlich Institute to expand the PharmNet.Bund portal, enhancing its role as a central source of pharmaceutical information for both federal and state resources. This initiative aims to improve the availability and quality of drug-related information, ultimately contributing to better healthcare outcomes across the country.